miR-142-3p包裹在T淋巴细胞衍生组织的sEV中诱导桥本甲状腺炎Treg功能缺陷和甲状腺细胞破坏

核心信息

  • 论文英文标题: miR-142-3p encapsulated in T lymphocyte-derived tissue small extracellular vesicles induces Treg function defect and thyrocyte destruction in Hashimoto's thyroiditis
  • 期刊: BMC Med
  • 发表年份: 2023
  • DOI: 10.1186/s12916-023-02914-7
  • PMID/PMCID: 37280674; PMC10242775

研究概览

The aim of the present study was to elucidate the role and mechanisms of tissue small extracellular vesicle (sEV) microRNAs (miRNAs) in the pathogenesis of HT. Our findings highlight the fact that tissue sEV-mediated miR-142-3p transfer can serve as a communication mode between T lymphocytes and thyrocyte cells in HT, favoring the progression of HT.

核心发现

We identified that miR-142-3p encapsulated in T lymphocyte-derived tissue sEVs can induce Treg function defect and thyrocyte destruction through an intact response loop.

H-2h4 mice from HT development display reduced lymphocyte infiltration, lower antibody titers, and higher Treg cells.

Looking at the mechanisms underlying sEV action on thyrocyte destruction, we found that the strong deleterious effect mediated by tissue sEV miR-142-3p is due to its ability to block the activation of the ERK1/2 signaling pathway by downregulating RAC1.

研究设计

Differentially expressed tissue sEV miRNAs were identified between HT tissue and normal tissue by RNA sequencing in the testing set (n = 20).

Subsequently, using quantitative real-time polymerase chain reaction (qRT‒PCR) assays and logistic regression analysis in the validation set (n = 60), the most relevant tissue sEV miRNAs to HT were verified.

The parental and recipient cells of that tissue sEV miRNA were then explored.

Echo Biotech 角色

组织外泌体分离鉴定及miRNA测序（10例桥本甲状腺炎vs10例正常组织）

关联平台: Exoomics®

关联服务与能力: Tissue EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing

关联产品或试剂: 无明确产品引用

参考文献

原始论文: miR-142-3p encapsulated in T lymphocyte-derived tissue small extracellular vesicles induces Treg function defect and thyrocyte destruction in Hashimoto's thyroiditis BMC Med. 2023. DOI: 10.1186/s12916-023-02914-7. PMID/PMCID: 37280674; PMC10242775.